Citigroup
MAZE

Citigroup’s Maze Therapeutics MAZE Stock Holding History

Citigroup’s Portfolio MAZE Stock Details MAZE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$256K Sell
8,563
-2,689
-24% -$119K ﹤0.01% 3887
2025
Q4 		$466K Buy
11,252
+10,983
+4,083% +$377K ﹤0.01% 3609
2025
Q3 		$6.98K Sell
269
-12,721
-98% -$215K ﹤0.01% 5123
2025
Q2 		$159K Buy
12,990
+6,774
+109% +$70.5K ﹤0.01% 4166
2025
Q1 		$68.4K Buy
+6,216
New +$74.8K ﹤0.01% 4783

Other funds holding MAZE

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
TGI
TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACM
AH Capital Management Menlo Park, California $1.29B AUM 26.81% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Citigroup's MAZE Position: Q1 2026 in Review

Citigroup reduced its Maze Therapeutics (MAZE) stake by 24% in Q1 2026, selling an estimated $119K and leaving 8,563 shares worth $256K. The position accounts for ﹤0.01% of the portfolio, ranked #3887.

Citigroup first reported a position in MAZE in Q1 2025 and has held it in 5 quarters since. The position peaked at $466K in Q4 2025. 165 funds tracked by Wall St. Rank hold MAZE as of Q1 2026.

  • Citigroup held 8,563 shares of Maze Therapeutics worth $256K as of Q1 2026.
  • Citigroup sold 2,689 Maze Therapeutics shares in Q1 2026, an estimated $119K.
  • Maze Therapeutics made up ﹤0.01% of Citigroup's portfolio in Q1 2026, its #3887 holding.
  • Citigroup first reported a position in Maze Therapeutics in Q1 2025 and has held it in 5 quarters since.
  • Citigroup's Maze Therapeutics position peaked at $466K in Q4 2025.
  • 165 funds tracked by Wall St. Rank held Maze Therapeutics as of Q1 2026.

Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.